Neoadjuvant therapy in resectable pancreatic cancer: A promising curative method to improve prognosis

Table 7 Comparison of lymph node status between the upfront surgery group and the neoadjuvant therapy plus surgery group

Ref.	Country	NCT number/Name	Variable	Upfront surgery	NAT plus surgery	P value
Golcher et al[7]	Germany	NCT00335543	pN0	10/33 (30%)	13/33 (39%)	0.44
Versteijne et al[8]	Netherlands	PREOPANC	pN0	NM	NM	NM
Casadei et al[9]	Italy	-	pN0	2/20 (10%)	5/18 (28%)	0.095
Reni et al[10]	Italy	PACT-15	pN0	13/49 (27%)	13/27 (48%)	NM

NAT: Neoadjuvant therapy; pN0: Pathological N0; NM: Not mentioned.